AGI Therapeutics plc

AGI (the company) is a specialty pharmaceutical company which is focused on the development and commercialisation of differentiated drug products for gastrointestinal (GI) diseases and disorders. AGI’s common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI.

The company has a portfolio of product candidates derived from its Known Molecular Entity (KME) approach to drug re-profiling and development. Rezular™, our lead product, is in Phase III clinical trials for the treatment of IBS-D.